The high mannose level of the antibody is low; (≤5%)

The G0 level of the antibody is high. (≥60%)

In some embodiments, the antibody has a low galactose level, ≤5%.

In some embodiments, the antibody has a high G0 level, ≥80%.

In some embodiments, the recombinant antibody with a unique glycan profile produced by the genome-edited CHO host cell satisfies the preferred condition that the fucose content is 0.

In some embodiments, the recombinant antibody with a unique glycan profile produced by the genome-edited CHO host cell has extremely low heterogeneity of N-polysaccharide and uniform carbohydrate chain.

In some embodiments, the recombinant antibody with a unique glycan profile produced by the genome-edited CHO host cell has a strong ADCC effect of Fc.

In some embodiments, the antibody has a glycan profile as shown for BAT4306F in the upper FIG. 10 of the Specification.

In some embodiments, the BAT4306F comprises two light chains as shown in SEQ ID NO. 20 and two heavy chains as shown in SEQ ID NO. 21; however, it is not excluded that these sequences are mutated as long as these mutations do not affect the function of the antibody.

In a thirteenth aspect, the present invention provides a FUT8 gene knockout CHO host cell, and the first exon of the FUT8 gene in this CHO host cell contains an inactivating mutation. This mutation may be one or more amino acid substitutions or deletions, or a frameshift mutation as shown in FIG. 6.

The present invention also provides a pharmaceutical composition comprising the antibody. As a preferred embodiment, the pharmaceutical composition also contains a pharmaceutically acceptable carrier.

The present invention also provides a method for preventing/treating a disease, comprising administering an effective amount of the antibody/fragment thereof disclosed herein to a subject in need thereof. In some embodiments, the disease is selected from the group consisting of cancer, anaphylaxis, cardiovascular disease, inflammatory disease, metabolic disease, neurological disease, viral infection, and/or bacterial infection. For example, the disease may be cancer or anaphylaxis. In some embodiments, the subject is mammal, such as a human being.

Compared with the existing antibody drugs, the present invention has the following advantages:

At present, the marketed antibody drugs are basically limited to the single N-glycosylation modification of Fc, however, due to inconsistent glycotype compositions and contents and easy changes, are complicated to a certain extent, especially posing a challenge to their stable production. According to the present invention, the recombinant antibody with unique glycan profile produced by the genome-edited CHO host cell has low N-glycosylation heterogeneity and good carbohydrate chain uniformity; at the same time, its ADCC effect is enhanced, and thus it greatly improves the quality and pharmaceutical properties of antibody drugs.

Compared with the corresponding antibody produced by the unmodified CHO-K1 (ATCC #CCL-61) or suspension-adapted parent cell CHO-BAT, the binding affinity of the antibody to the FcγRIIIA receptor is increased.

The modified host cells produce antibodies that have an enhanced affinity for FcγRIIIA compared with the corresponding antibodies produced by the unmodified host cells.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows an anchorage-dependent CHO-K1(ATCC #CCL-61) and a CHO-BAT cell line adapted to suspension growth in serum-free medium.

FIG. 2 shows a profile of TALEN expression plasmid pCS2-FokI.

FIG. 3 shows an electrophoretogram for functional verification of TALEN protein. The electrophoresis chart of wild-type cells is located in the left side. After gene editing, expectedly, the PCR products of cell genome showed two bands of 500 BP and 750 BP, while that of the wild type only showed a single band of 750 BP. This proves that the Talen protein pair is functional. Lane 1: 100 bp marker; Lane 2: wt; Lane 3: pool.

FIG. 4 shows the cells growing on 24-well plates analyzed by FACS, wherein the gene-edited cell clones labeled with FITC-labeled LCA bind the negative cells, and the wild-type cells labeled with FITC-labeled LCA bind the cells positively.

FIG. 5 shows the carbohydrate chain chip analysis, wherein the fucose content of the submitted gene-edited clones 41 and 43 is reduced to 0-10%, while the fucose content of the wild-type antibody 1206 is 80%.

FIG. 6 shows the sequencing of the target sequence of TALEN protein after PCR amplification, with the results being compared by the lasergeneMegAlign sequence analysis software. 191-1, 191-2, 217-1, 217-3 are four selected clones with regulated genomes. Genomes were extracted as DNA templates, PCR reaction was performed with primers L130 for and L130rev, and CEL-1 base mismatch analysis was performed on the amplification products. The results show that cell clones 191-1 and 191-2 were heterozygous and cell clones 217-1 and 217-3 were homozygous. According to the comparison of results, the genome-edited homozygote 217-1 and 217-3 were selected and designated as CHO-2G8 and CHO-1D6. CHO-2G8 was finally selected as the host cell for subsequent experiments, and the host cell was named as CHO-BAT-KF.

FIG. 7 shows the comparison of the growth density of CHO-BAT-KF to the parent cell CHO-BAT.

FIG. 8 shows the comparison of the growth viability of CHO-BAT-KF to the parent cell CHO-BAT.

FIG. 9 shows analysis of N-polysaccharides from BAT4306F and 4306 antibody molecules performed by MALDI-TOF MS. Each N-polysaccharide from BAT4306F was one fucose less than that from 4306. The chart on the left is the antibody molecules 4306 produced by parent cells and the chart on the right is BAT4306F antibody molecules.

FIG. 10 shows that BAT4306F has lower fucose content, lower carbohydrate chain heterogeneity and better product uniformity than GAZYVA (Obinutuzumab).

FIG. 11 shows the comparison of ADCC effects among anti-CD20 antibodies such as BAT4306 wild type, carbohydrate chain modified BAT4306F, Obinutuzumab and Rituximab using Raji as target cells and PBMC as effector cells.

FIG. 12 shows the comparison of the ability among three carbohydrate chain modified antibodies BAT4306F, Obinutuzumab and rituximab to deplete B cells in whole blood in vitro at concentrations of 50, 25, and 10 ng/mL.

FIG. 13 shows the comparison of the glycan profile among the anti-CD20 antibodies BAT4306F and BAT4406F, the anti-EGFR antibody BAT0206F, and the anti-Trop2 antibody BAT0808 produced by CHO-BAT-KF cells.

The genome-edited CHO host cell of the invention is preserved in China Center for Type Culture Collection (CCTCC NO: C2017127; date: Aug. 10, 2017; address: Wuhan University, Wuhan, China; classified designation: CHO-BAT-KF FUT8(−/−)).

DETAILED DESCRIPTION OF THE INVENTION

The technical scheme of the present invention is further described in combination with the detailed embodiments, which do not represent limitations to the protection scope of the present invention. Non-essential modifications and adjustments made by others according to the concept of the present invention shall still fall into the protection scope of the present invention.

It should be noted that in the present invention, “level” or “content” of the saccharide fraction of the antibody has the same meaning, indicating the mass ratio of a certain saccharide fraction in all saccharide fractions of the antibody.

According to the present invention, an “amino acid” refers to a carboxyl-α-amino acid, which may be encoded by a nucleic acid directly or in the form of precursor. A single amino acid is encoded by nucleic acid consisting of three nucleotides (so-called codons or base triple). Each amino acid is encoded by at least one codon. The encoding of the same amino acid by different codons is called “degeneracy of genetic code”. The term “amino acid” used in the present application refers to the naturally occurring carboxyl-α-amino acid, which includes alanine (three-letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), asparagine (asn, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y) and valine (val, V).

In the present invention, the terms “polynucleotide” or “nucleic acid” or “nucleic acid sequence” are used interchangeably and refer to polymer molecules consisting of mononucleotide (also called bases) a, c, g, and t (or u in RNA), such as DNA, RNA, or modified forms thereof. The polynucleotide molecule may be a naturally occurring polynucleotide molecule, or a synthetic polynucleotide molecule, or a combination of one or more naturally occurring polynucleotide molecules and one or more synthetic polynucleotide molecules. The definition also includes naturally occurring polynucleotide molecules in which one or more nucleotides are altered (e.g., by mutagenesis), deleted, or added. The nucleic acids may be isolated or integrated into another nucleic acids such as expression cassettes, plasmids or chromosomes of the host cells. The nucleic acids are characterized by a nucleic acid sequence consisting of a mononucleotide. The operation and method for converting amino acid sequences such as polypeptides into corresponding nucleic acid sequences encoding the amino acid sequences are well known to those skilled in the art. Therefore, nucleic acids can be characterized by their nucleic acid sequences consisting of mononucleotide or by the amino acid sequences of the polypeptides encoded by them.

Also, the terms “polynucleotide” or “nucleic acid” or “nucleic acid sequence” may contain modified nucleotides in percentage of the total number of nucleotides present in the nucleic acid molecule, such as at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% modified nucleotides.

The term “polypeptide” in the present invention is a polymer comprising amino acids linked by peptide bonds, which can be produced naturally or synthetically. Polypeptides with less than about 20 amino acid residues may be referred to as “peptides”, however, molecules consisting of two or more peptides or molecules containing one polypeptide with more than 100 amino acid residues may be referred to as “proteins”. Polypeptides may also contain non-amino acid components such as glycosyls, metal ions, or carboxylic acid esters. Non-amino acid components can be added by cells expressing this polypeptide and can vary with the type of cells. A polypeptide is defined herein according to its amino acid backbone structure or nucleic acid encoding it. The addition of glycosyl, for example, is generally not specified, but may be allowed. Also, the “polypeptide” may contain modified amino acids in percentage of the total number of amino acids present in the amino acid molecule, such as at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% modified amino acids.

In the present invention, the term “host cell” refers to a microorganism or eukaryotic cell or cell line cultured in a mononuclear entity, which may be or has been used as a recipient of a recombinant vector or other transferred polynucleotide, and includes an offspring of the transfected original cell. In some embodiments, the host cells are non-lymphocytes, and the host cells produce the same unique glycan profile. In some embodiments, the host cells are, such as NS0 cells, simian COS cells, Chinese hamster ovary (CHO) cells, etc. In some embodiments, the host cells are selected from Chinese hamster ovary (CHO) cells. In some embodiments, the host cells are selected from CHO-K1, CHO-S, DUXB11, CHO-1E5, CHO3F, CHO/DG44, CHO-BAT and CHO-2.6 cells. In some embodiments, the host cells generate antibodies that exhibit a unique glycan profile. The genome-edited CHO host cells of the present invention, such as CHO-BAT-KF FUT8(−/−) can be grown in a culture and devices (including fermenters) that can be used to grow the culture. They can grow into a single layer or attach to a surface; alternatively, the host cells may grow in suspension. The cells can grow in serum-free medium. The medium may be a commercially available medium such as, but not limited to, DMEM/F12. The edited CHO host cells can maintain its specific unique glycan profile in the medium for many generations. For example, the edited CHO host cells retain their specific unique glycan profile for at least about 20, 30, 40 or 50 generations. In some embodiments, the modified CHO host cells retain their unique glycan profile for at least about 60 generations. In another embodiment, the modified CHO host cells retain their unique glycan profile for at least about 100, 150, 200, 500, 1000 or more generations.

The glycosylation mode of the host cells may be N- or O-glycosylation of any protein moiety, wherein one or more glucose molecules may be added to amide nitrogen of asparagine or hydroxyl oxygen of hydroxylysine, hydroxyproline, serine or threonine, respectively. The glycosylation mode is characterized by a change in the level of at least two or more glucose molecules or saccharides, such as monosaccharides, disaccharides, polysaccharides or oligosaccharides. For example, the glucose molecules may be trisaccharides, tetrasaccharides, pentoses, hexasaccharides, heptoses, octasaccharides, nonasaccharides, or derivatives thereof, such as deoxysaccharides (e.g., deoxyhexasaccharides); N- or O-substituted derivatives such as sialic acid; or saccharides with amino groups. The glucose molecules may include, but are not limited to, galactose (Gal), glucose (Glc), mannose (Man), N-acetylneuraminic acid (NeuAc), fucose (Fuc), N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc) and xylose. The glucose molecules can be linked to other glucose molecules by a or 13 linking.

The term “antibody” of the present invention includes all forms of antibodies, such as recombinant antibodies, humanized antibodies, chimeric antibodies, single chain antibodies, fusion antibodies, monoclonal antibodies and polyclonal antibodies. The antibodies may also be fragments. The antibodies can also bind drugs, toxins or therapeutic radioisotopes. The host cells of the present invention may also produce bispecific antibody fusion proteins, including hybrid antibodies that bind more than one antigen. Thus, antibodies include naked antibodies and binding antibodies as well as antibody fragments, and they may be single-specific or multi-specific.

As alternative embodiments, the antibodies or fragments thereof are not particularly limited to and may be selected from anti-HER2, anti-CD20, anti-EGF, anti-VEGF, anti-PDGF, anti-EpCam, anti-CD3, anti-CD4, anti-CD19, anti-CD30, anti-CD33, anti-CD40, anti-CD51, anti-CD55, anti-CD80, anti-CD95, anti-CCR2, anti-CCR3, anti-CCR4, anti-CCR5, anti-folic acids, anti-CXCR4, anti-EGFR or Trop2 antibodies, etc. As preferred embodiments, the antibodies are humanized or full human antibodies.

In a pharmaceutical composition of the present invention, a pharmaceutical preparation for storing the antibodies of the present invention is prepared in the form of a lyophilized preparation or an aqueous solution by mixing the antibodies with a desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Acceptable carriers, excipients or stabilizers are non-toxic to the recipient at the dose and concentration applied, and include buffer solutions such as phosphates, citrates and other organic acids; antioxidants such as corbic acid and methionine; preservatives (such as benzyldimethyl octadecyl ammonium chloride; hexamethyl ammonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butanol or benzyl alcohol; alkyl p-hydroxybenzoates, such as methyl or propyl p-hydroxybenzoate; catechol; resorcinol; cyclohexanol; 3-propanol and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates such as glucose, mannose or dextrin; chelating agents such as EDTA; saccharides such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or nonionic surfactants such as Tween, Pluronics™ or polyethylene glycol (PEG).

The antibodies, pharmaceutical compositions and pharmaceutical preparations of the present invention may be administered by any suitable means, including parenteral, subcutaneous, intraperitoneal, intrapulmonary and intranasal means; and, if necessary, intralesional administration may be used for local immunosuppressive treatment. The parenteral perfusion includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administrations. In addition, the antibody of the present invention can be suitably administered by pulsed perfusion (in particular, dose gradient changes of the antibodies of the present invention). Depending on the administration time, preferably, the injection administration is used; more preferably, intravenous or subcutaneous injection is used. ADCC (antibody-dependent cell-mediated cytotoxicity) refers to a cell-mediated reaction in which the effector cells expressing FCR (e.g., natural killer (NK) cells, neutrophils, and macrophages) recognize the antibodies bound to target cells and then lyse the target cells. Primary cells used to mediate ADCC include NK cells, monocytes and macrophages. In general, NK cells mainly express FcγRIII, while monocytes express FcγRI, FcγRII and FcγRIII. In the present invention, the maternal CHO cell line is edited to produce a CHO cell line with a unique glycan profile. The edited CHO cell line can then produce antibodies with higher ADCC activity than antibodies produced by the maternal CHO cells.

Example 1. Screening of Parent Cells Adapted to Serum-Free Suspension Culture

CHO-K1 was cultured in DMEM/F12 medium containing 10% FBS. When the cell confluence reached 80%-90%, washed with PBS and digest with trypsin. Then, terminated by DMEM/F12 medium containing 5% FBS, counted and centrifuged. Resuspended the cells in DMEM/F12 medium containing 5% FBS and seeded the cells at a density of 1×10⁵cells/ml. When the cell confluence reached 80%-90%, washed with PBS and digest with trypsin. Then, terminated by the DMEM/F12 medium containing 2% FBS, counted and centrifuged. Resuspended the cells in the DMEM/F12 medium containing 2% FBS and seeded at a density of 1×10⁵cells/ml. When the cell confluence reached 80%-90%, digested the cells with trypsin according to the previous steps, terminated by the DMEM/F12 medium containing 1% FBS, and carried out passage for 3-4 generations. Mixed the CD CHO medium with DMEM/F12 at a ratio of 1:1 (V/V), adjusted the final concentration to 6 mM glutamine, and adjusted the serum content to 1%. The CHO-K1 cells obtained above adapted to low serum culture were seeded into a T25 flask at a density of 3×10⁵cells/mL and were incubated in a 5% CO₂incubator at 37° C. When the cell confluence reached 80-90%, digested the cells with trypsin and terminate by the mixed medium of DMEM/F12 containing 1% FBS and CD CHO medium (volume ratio 1:2), counted and centrifuged, seeded into a T25 flask at a density of 3×10⁵cells/ml, and incubated in a 5% CO₂incubator at 37° C. Gradually reduced the ratio of DMEM/F12 in the mixture medium to (1:8) until the cell survival rate was more than 90%, which means that the DMEM/F12 component in the cell medium could be completely eliminated, and the CHO-K1 cell which adapted in chemical composition limitative CD CHO medium containing 1% serum was established. Then CHO-K1 was cultured in chemical composition limitative CD CHO medium containing 1% FBS. When cell confluence reached 80%-90%, washed with PBS and digested with trypsin. Then, terminated by the CD CHO medium containing 0.5% FBS, counted and centrifuged. Resuspended the cells in the CD CHO medium containing 0.5% FBS and seeded in a T25 flask at a density of 1×10⁵cells/ml. When the cell viability reached 80%-90%, washed the cells with PBS and digested with trypsin. Then, terminated by the CD CHO medium containing 0.25% FBS, counted and centrifuged. Resuspended the cells in the CD CHO medium containing 0.25% FBS and seeded at a density of 1×10⁵cells/ml. Until the cells grew healthily at this stage, started the next stage of decreasing serum concentration. After limiting dilution of CHO-K1 cells adapted to serum-free CD CHO culture, seeded into thirty 96-well plates, and adjusted the cell density to 1 cell/well. After two weeks, marked the monoclonal cells through microscopic examination. Transferred the clones with large cell area to a 24-well plate. After one week, marked the clones with high growth density and with consistent cell size through microscopic examination, and then transferred to a 6-well plate for further culture. After one week, clones that were completely suspended, less agglomerated, and had a denser cell density were marked through microscopic examination, and transferred each clone to a 100-ml triangular flask with a culture volume of 10 ml, respectively. Recorded the density and viability of each cell. CHO-K1 cells domesticated and adapted to serum-free culture were renamed CHO-BAT.

Example 2. Construction of FUT8 TALEN Recombinant Plasma

The complete genome sequence (NW.003613860) of CHO-K1 of Chinese hamster ovarian cancer cells was analyzed to obtain the FUT8 genome sequence (Gene ID: 100751648) and its cDNA (see Table 1, SEQ ID NO. 8) sequence. The FUT8 genome consists of 9 exons and 11 introns. As the activity center of FUT8 enzyme is composed of amino acids (underlined amino acid sequence of SEQ ID NO. 9) encoded by exon 1 (SEQ ID NO. 7), the left and right flanks of exon 1 of FUT8 gene were designed as TALEN target sequences. FUT8 TALEN protein L130P (SEQ ID NO. 10) and R184P (SEQ ID NO. 11) were designed according to the TALEN design guidelines and the gene editing mechanism. L130P and FokI endonucleases formed a fusion protein L130-FokI (SEQ ID NO. 14), which recognized the left-wing base L130PTN (SEQ ID NO. 3) in exon 1, and the corresponding nucleic acid sequence L130-FokIN of the fusion protein L130-FokI is shown in SEQ ID NO. 15 with a length of 19 bp. R184P and FokI endonucleases formed a fusion protein R184-FokI (SEQ ID NO. 16), which recognized the right-wing base R184PTN (SEQ ID NO. 4) in exon 1, and the corresponding nucleic acid sequence R184P-FokIN of the fusion protein R184P-FokI is shown in SEQ ID NO. 17 with a length of 17 bp. The plasmid vector (see FIG. 2) containing TALEN protein encoding the left-wing L130PTN and the right-wing R184PTN of the exon 1 was constructed as described in Tomas Cermak et al. (2011). The restriction endonucleases NcoI and XbaI cleavage sites were added at both ends of L130-FokIN and R184P-FokIN. Synthesized these two sequences, and cloned them into pCS2-peas-T vector using NcoI and XbaI (FIG. 2). The left-wing binding sequence and the right-wing binding sequence had a gap sequence of 19 bp in length (Space, SEQ ID NO. 5). The DNA sequencing results of the two plasmids L130N and R184N of FUT8 TALEN are shown in Table 1, SEQ ID NO. 12 and SEQ NO. 13. The nucleic acid sequences such as L130N and R184N were translated into amino acids, and the amino acid sequences L130P and R184P of the corresponding sequences are shown in Table 1, SEQ ID NO. 10 and SEQ ID NO. 11.

TABLE 1

Sequence table

L130for
gggtagctaattgtctttcag
SEQ ID

NO. 1

L130rev
taaatgccactgcttctata
SEQ ID

NO. 2

L130PTN
tccaagattcttgcaaagct
SEQ ID

NO. 3

R184PTN
aatgaagacttgaggaga
SEQ ID

NO. 4

Space
ggagcgcttaaaacaacaa
SEQ ID

NO. 5

PCR
GGGTAGCTAATTGTCTTTCAGCCTCCTGGCCAAAGATACCATGAAAGTCAACT
SEQ ID

product
TACGTTGTATTCTATATCTCAAACAACTCAGGGTGTTTCTTACTCTTTCCACA
NO. 6

GCATGTAGAGCCCAGGAAGCACAGGACAAGAAAGCTGCCTCCTTGTATCACCA

GGAAGATCTTTTTGTAAGAGTCATCACAGTATACCAGAGAGACTAATTTTGTC

TGAAGCATCATGTGTTGAAACAACAGAAACTTATTTTCCTGTGTGGCTAACTA

GAACCAGAGTACAATGTTTCCAATTCTTTGAGCTCCGAGAAGACAGAAGGGAG

TTGAAACTCTGAAAATGCGGGCATGGACTGGTTCCTGGCGTTGGATTATGCTC

ATTCTTTTTGCCTGGGGGACCTTATTGTTTTATATAGGTGGTCATTTGGTTCG

AGATAATGACCACCCTGACCATTCTAGCAGAGAACTCTCCAAGATTCTTGCAA

AGCTGGAGCGCTTAAAACAACAAAATGAAGACTTGAGGAGAATGGCTGAGTCT

CTCCGGTAGGTTTGAAATACTCAAGGATTTGATGAAATACTGTGCTTGACCTT

TAGGTATAGGGTCTCAGTCTGCTGTTGAAAAATATAATTTCTACAAACCGTCT

TTGTAAAATTTTAAGTATTGTAGCAGACTTTTTAAAAGTCAGTGATACATCTA

TATAGTCAATATAGGTTTACATAGTTGCAATCTTATTTTGCATATGAATCAGT

ATATAGAAGCAGTGGCATTTA

Exon1
ATGCGGGCATGGACTGGTTCCTGGCGTTGGATTATGCTCATTCTTTTTGCCTG
SEQ ID

GGGGACCTTATTGTTTTATATAGGTGGTCATTTGGTTCGAGATAATGACCACC
NO. 7

CTGACCATTCTAGCAGAGAACTCTCCAAGATTCTTGCAAAGCTGGAGCGCTTA

AAACAACAAAATGAAGACTTGAGGAGAATGGCTGAGTCTCTCCGG

FUT8
ATGCGGGCATGGACTGGTTCCTGGCGTTGGATTATGCTCATTCTTTTTGCCTG
SEQ ID

cDNA
GGGGACCTTATTGTTTTATATAGGTGGTCATTTGGTTCGAGATAATGACCACC
NO. 8

CTGACCATTCTAGCAGAGAACTCTCCAAGATTCTTGCAAAGCTGGAGCGCTTA

AAACAACAAAATGAAGACTTGAGGAGAATGGCTGAGTCTCTCCGAATACCAGA

AGGCCCTATTGATCAGGGGACAGCTACAGGAAGAGTCCGTGTTTTAGAAGAAC

AGCTTGTTAAGGCCAAAGAACAGATTGAAAATTACAAGAAACAAGCTAGGAAT

GATCTGGGAAAGGATCATGAAATCTTAAGGAGGAGGATTGAAAATGGAGCTAA

AGAGCTCTGGTTTTTTCTACAAAGTGAATTGAAGAAATTAAAGAAATTAGAAG

GAAACGAACTCCAAAGACATGCAGATGAAATTCTTTTGGATTTAGGACATCAT

GAAAGGTCTATCATGACAGATCTATACTACCTCAGTCAAACAGATGGAGCAGG

TGAGTGGCGGGAAAAAGAAGCCAAAGATCTGACAGAGCTGGTCCAGCGGAGAA

TAACATATCTGCAGAATCCCAAGGACTGCAGCAAAGCCAGAAAGCTGGTATGT

AATATCAACAAAGGCTGTGGCTATGGATGTCAACTCCATCATGTGGTTTACTG

CTTCATGATTGCTTATGGCACCCAGCGAACACTCATCTTGGAATCTCAGAATT

GGCGCTATGCTACTGGAGGATGGGAGACTGTGTTTAGACCTGTAAGTGAGACA

TGCACAGACAGGTCTGGCCTCTCCACTGGACACTGGTCAGGTGAAGTGAAGGA

CAAAAATGTTCAAGTGGTCGAGCTCCCCATTGTAGACAGCCTCCATCCTCGTC

CTCCTTACTTACCCTTGGCTGTACCAGAAGACCTTGCAGATCGACTCCTGAGA

GTCCATGGTGATCCTGCAGTGTGGTGGGTATCCCAGTTTGTCAAATACTTGAT

CCGTCCACAACCTTGGCTGGAAAGGGAAATAGAAGAAACCACCAAGAAGCTTG

GCTTCAAACATCCAGTTATTGGAGTCCATGTCAGACGCACTGACAAAGTGGGA

ACAGAAGCAGCCTTCCATCCCATTGAGGAATACATGGTACACGTTGAAGAACA

TTTTCAGCTTCTCGAACGCAGAATGAAAGTGGATAAAAAAAGAGTGTATCTGG

CCACTGATGACCCTTCTTTGTTAAAGGAGGCAAAGACAAAGTACTCCAATTAT

GAATTTATTAGTGATAACTCTATTTCTTGGTCAGCTGGACTACACAACCGATA

CACAGAAAATTCACTTCGGGGCGTGATCCTGGATATACACTTTCTCTCCCAGG

CTGACTTCCTTGTGTGTACTTTTTCATCCCAGGTCTGTAGGGTTGCTTATGAA

ATCATGCAAACACTGCATCCTGATGCCTCTGCAAACTTCCATTCTTTAGATGA

CATCTACTATTTTGGAGGCCAAAATGCCCACAACCAGATTGCAGTTTATCCTC

ACCAACCTCGAACTAAAGAGGAAATCCCCATGGAACCTGGAGATATCATTGGT

GTGGCTGGAAACCATTGGAATGGTTACTCTAAAGGTGTCAACAGAAAACTAGG

AAAAACAGGCCTGTACCCTTCCTACAAAGTCCGAGAGAAGATAGAAACAGTCA

AATACCCTACATATCCTGAAGCTGAAAAATAG

FUT8
MRAWTGSWRWIMLILFAWGTLLFYIGGHLVRDNDHPDHSSRELSKILAKLERL
SEQ ID

protein
KQQNEDLRRMAESLRIPEGPIDQGTATGRVRVLEEQLVKAKEQIENYKKQARN
NO. 9

DLGKDHEILRRRIENGAKELWFFLQSELKKLKKLEGNELQRHADEILLDLGHH

ERSIMTDLYYLSQTDGAGEWREKEAKDLTELVQRRITYLQNPKDCSKARKLVC

NINKGCGYGCQLHHVVYCFMIAYGTQRTLILESQNWRYATGGWETVFRPVSET

CTDRSGLSTGHWSGEVKDKNVQVVELPIVDSLHPRPPYLPLAVPEDLADRLLR

VHGDPAVWWVSQFVKYLIRPQPWLEREIEETTKKLGFKHPVIGVHVRRTDKVG

TEAAFHPIEEYMVHVEEHFQLLERRMKVDKKRVYLATDDPSLLKEAKTKYSNY

EFISDNSISWSAGLHNRYTENSLRGVILDIHFLSQADFLVCTFSSQVCRVAYE

IMQTLHPDASANFHSLDDIYYFGGQNAHNQIAVYPHQPRTKEEIPMEPGDIIG

VAGNHWNGYSKGVNRKLGKTGLYPSYKVREKIETVKYPTYPEAEK

L130P
LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQAL
SEQ ID

ETVQRLLPVLCQAHGLTPAQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPD
NO. 10

QVVAIASNIGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNNGGKQALETVQ

RLLPVLCQAHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPDQVVA

IASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGKQALETVQRLLP

VLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASN

GGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGKQALETVQRLLPVLCQ

AHGLTPAQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPDQVVAIASHDGGK

QALETVQRLLPVLCQAHGLTPAQVVAIASNIGGKQALETVQRLLPVLCQAHGL

TPDQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNIGGKQALE

TVQRLLPVLCQAHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPDQ

VVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGRPALESIVA

QLSRPDPALAAL

R184P
LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGKQAL
SEQ ID

ETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPA
NO. 11

QVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGKQALETVQ

RLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVA

IASNIGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNIGGKQALETVQRLLP

VLCQAHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPDQVVAIASN

GGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQ

AHGLTPAQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGK

QALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQAHGL

TPAQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNGGGKQALE

TVQRLLPVLCQAHGLTPAQVVAIASNGGGRPALESIVAQLSRPDPALAAL

L130N
CTGACCCCGGAGCAGGTGGTGGCCATCGCTAGTCATGACGGTGGCAAACAGGC
SEQ ID

TCTTGAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAA
NO. 12

CCCCAGCGCAAGTTGTAGCGATTGCTAGTCATGACGGTGGCAAACAGGCTCTT

GAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCC

AGCGCAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGCACTTGAGA

CGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCACCCCAGAT

CAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGCACTTGAGACGGT

TCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCACCCCAGATCAAG

TTGTAGCGATTGCTAGTAACAATGGTGGCAAACAGGCTCTCGAAACCGTACAA

CGACTCCTCCCAGTTCTCTGTCAAGCCCACGGACTAACTCCTGATCAAGTTGT

AGCGATTGCTAGTAATATTGGTGGCAAACAGGCACTTGAGACGGTTCAGCGCC

TCCTTCCAGTTCTTTGTCAAGCTCACGGACTCACCCCAGATCAAGTTGTAGCG

ATTGCTAGTAATGGGGGTGGCAAACAGGCTCTTGAAACCGTGCAACGACTGCT

CCCAGTTCTCTGTCAAGCCCACGGCCTCACCCCGGCGCAAGTTGTAGCGATTG

CTAGTAATGGGGGTGGCAAACAGGCTCTTGAAACCGTGCAACGACTGCTCCCA

GTTCTCTGTCAAGCCCACGGCCTCACCCCGGCGCAAGTTGTAGCGATTGCTAG

TCATGACGGTGGCAAACAGGCTCTTGAGACCGTCCAACGCCTTCTACCAGTTC

TCTGTCAAGCCCACGGACTAACCCCAGCGCAAGTTGTAGCGATTGCTAGTAAT

GGGGGTGGCAAACAGGCTCTTGAAACCGTGCAACGACTGCTCCCAGTTCTCTG

TCAAGCCCACGGCCTCACCCCGGCGCAAGTTGTAGCGATTGCTAGTAATGGGG

GTGGCAAACAGGCTCTTGAAACCGTGCAACGACTGCTCCCAGTTCTCTGTCAA

GCCCACGGCCTCACCCCGGCGCAAGTTGTAGCGATTGCTAGTAACAATGGTGG

CAAACAGGCTCTCGAAACCGTACAACGACTCCTCCCAGTTCTCTGTCAAGCCC

ACGGACTAACTCCTGATCAAGTTGTAGCGATTGCTAGTCATGACGGTGGCAAA

CAGGCTCTTGAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGG

ACTAACCCCAGCGCAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGG

CACTTGAGACGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTC

ACCCCAGATCAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGCACT

TGAGACGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCACCC

CAGATCAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGCACTTGAG

ACGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCACCCCAGA

TCAAGTTGTAGCGATTGCTAGTAACAATGGTGGCAAACAGGCTCTCGAAACCG

TACAACGACTCCTCCCAGTTCTCTGTCAAGCCCACGGACTAACTCCTGATCAA

GTTGTAGCGATTGCTAGTCATGACGGTGGCAAACAGGCTCTTGAGACCGTCCA

ACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCGCAAGTTG

TAGCGATTGCTAGTAATGGCGGCGGTCGACCGGCGCTGGAGAGCATTGTTGCC

CAGTTATCTCGCCCTGATCCGGCGTTGGCCGCGTTG

R184N
CTGACCCCGGAGCAGGTGGTGGCCATCGCTAGTCATGACGGTGGCAAACAGGC
SEQ ID

TCTTGAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAA
NO. 13

CCCCAGCGCAAGTTGTAGCGATTGCTAGTAATGGGGGTGGCAAACAGGCTCTT

GAAACCGTGCAACGACTGCTCCCAGTTCTCTGTCAAGCCCACGGCCTCACCCC

GGCGCAAGTTGTAGCGATTGCTAGTCATGACGGTGGCAAACAGGCTCTTGAGA

CCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCG

CAAGTTGTAGCGATTGCTAGTCATGACGGTGGCAAACAGGCTCTTGAGACCGT

CCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCGCAAG

TTGTAGCGATTGCTAGTAATGGGGGTGGCAAACAGGCTCTTGAAACCGTGCAA

CGACTGCTCCCAGTTCTCTGTCAAGCCCACGGCCTCACCCCGGCGCAAGTTGT

AGCGATTGCTAGTCATGACGGTGGCAAACAGGCTCTTGAGACCGTCCAACGCC

TTCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCGCAAGTTGTAGCG

ATTGCTAGTAATATTGGTGGCAAACAGGCACTTGAGACGGTTCAGCGCCTCCT

TCCAGTTCTTTGTCAAGCTCACGGACTCACCCCAGATCAAGTTGTAGCGATTG

CTAGTAATATTGGTGGCAAACAGGCACTTGAGACGGTTCAGCGCCTCCTTCCA

GTTCTTTGTCAAGCTCACGGACTCACCCCAGATCAAGTTGTAGCGATTGCTAG

TAACAATGGTGGCAAACAGGCTCTCGAAACCGTACAACGACTCCTCCCAGTTC

TCTGTCAAGCCCACGGACTAACTCCTGATCAAGTTGTAGCGATTGCTAGTAAT

GGGGGTGGCAAACAGGCTCTTGAAACCGTGCAACGACTGCTCCCAGTTCTCTG

TCAAGCCCACGGCCTCACCCCGGCGCAAGTTGTAGCGATTGCTAGTCATGACG

GTGGCAAACAGGCTCTTGAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAA

GCCCACGGACTAACCCCAGCGCAAGTTGTAGCGATTGCTAGTAATGGGGGTGG

CAAACAGGCTCTTGAAACCGTGCAACGACTGCTCCCAGTTCTCTGTCAAGCCC

ACGGCCTCACCCCGGCGCAAGTTGTAGCGATTGCTAGTAATGGGGGTGGCAAA

CAGGCTCTTGAAACCGTGCAACGACTGCTCCCAGTTCTCTGTCAAGCCCACGG

CCTCACCCCGGCGCAAGTTGTAGCGATTGCTAGTCATGACGGTGGCAAACAGG

CTCTTGAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTA

ACCCCAGCGCAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGCACT

TGAGACGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCACCC

CAGATCAAGTTGTAGCGATTGCTAGTAATGGGGGTGGCAAACAGGCTCTTGAA

ACCGTGCAACGACTGCTCCCAGTTCTCTGTCAAGCCCACGGCCTCACCCCGGC

GCAAGTTGTAGCGATTGCTAGTAATGGCGGCGGTCGACCGGCGCTGGAGAGCA

TTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGCGTTG

L130P-
MAPKKKRKVYPYDVPDYAGYPYDVPDYAGSYPYDVPDYAAHGTVDLRTLGYSQ
SEQ ID

FokI
QQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIA
NO. 14

ALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGG

VTAVEAVHAWRNALTGAPLNLTPEQVVAIASHDGGKQALETVQRLLPVLCQAH

GLTPAQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNIGGKQA

LETVQRLLPVLCQAHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQAHGLTP

DQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNIGGKQALETV

QRLLPVLCQAHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVV

AIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLL

PVLCQAHGLTPAQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIAS

NGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNNGGKQALETVQRLLPVLC

QAHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNIGG

KQALETVQRLLPVLCQAHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG

LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNNGGKQAL

ETVQRLLPVLCQAHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPA

QVVAIASNGGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAVK

KGLPHAPALIKRTNRRIPERTSHRVAGSQLVKSELEEKKSELRHKLKYVPHEY

IELIEIARNPTQDRILEMKVMEFFMKVYGYRGEHLGGSRKPDGAIYTVGSPID

YGVIVDTKAYSGGYNLPIGQAREMQRYVEENQTRNKHINPNEWWKVYPSSVTE

FKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEE

VRRKFNNGEINF*

L130P-
atggctccaaagaagaagcgtaaggtatacccatacgatgttcctgactatgc
SEQ ID

FokIN
gggctatccctatgacgtcccggactatgcaggatcgtatccatatgacgttc
NO. 15

cagattacgctgctcatggtaccgtggatctacgcacgctcggctacagccag

cagcaacaggagaagatcaaaccgaaggttcgttcgacagtggcgcagcacca

cgaggcactggtcggccacgggtttacacacgcgcacatcgttgcgctcagcc

aacacccggcagcgttagggaccgtcgctgtcaagtatcaggacatgatcgca

gcgttgccagaggcgacacacgaagcgatcgttggcgtcggcaaacagtggtc

cggcgcacgcgctctggaggccttgctcacggtggcgggagagttgagaggtc

caccgttacagttggacacaggccaacttctcaagattgcaaaacgtggcggc

gtgaccgcagtggaggcagtgcatgcatggcgcaatgcactgacgggtgcccc

cctgaacctgaccccggagcaggtggtggccatcgcTAGTCATGACGGTGGCA

AACAGGCTCTTGAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCAC

GGACTAACCCCAGCGCAAGTTGTAGCGATTGCTAGTCATGACGGTGGCAAACA

GGCTCTTGAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGAC

TAACCCCAGCGCAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGCA

CTTGAGACGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCAC

CCCAGATCAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGCACTTG

AGACGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCACCCCA

GATCAAGTTGTAGCGATTGCTAGTAACAATGGTGGCAAACAGGCTCTCGAAAC

CGTACAACGACTCCTCCCAGTTCTCTGTCAAGCCCACGGACTAACTCCTGATC

AAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGCACTTGAGACGGTT

CAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCACCCCAGATCAAGT

TGTAGCGATTGCTAGTAATGGGGGTGGCAAACAGGCTCTTGAAACCGTGCAAC

GACTGCTCCCAGTTCTCTGTCAAGCCCACGGCCTCACCCCGGCGCAAGTTGTA

GCGATTGCTAGTAATGGGGGTGGCAAACAGGCTCTTGAAACCGTGCAACGACT

GCTCCCAGTTCTCTGTCAAGCCCACGGCCTCACCCCGGCGCAAGTTGTAGCGA

TTGCTAGTCATGACGGTGGCAAACAGGCTCTTGAGACCGTCCAACGCCTTCTA

CCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCGCAAGTTGTAGCGATTGC

TAGTAATGGGGGTGGCAAACAGGCTCTTGAAACCGTGCAACGACTGCTCCCAG

TTCTCTGTCAAGCCCACGGCCTCACCCCGGCGCAAGTTGTAGCGATTGCTAGT

AATGGGGGTGGCAAACAGGCTCTTGAAACCGTGCAACGACTGCTCCCAGTTCT

CTGTCAAGCCCACGGCCTCACCCCGGCGCAAGTTGTAGCGATTGCTAGTAACA

ATGGTGGCAAACAGGCTCTCGAAACCGTACAACGACTCCTCCCAGTTCTCTGT

CAAGCCCACGGACTAACTCCTGATCAAGTTGTAGCGATTGCTAGTCATGACGG

TGGCAAACAGGCTCTTGAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAAG

CCCACGGACTAACCCCAGCGCAAGTTGTAGCGATTGCTAGTAATATTGGTGGC

AAACAGGCACTTGAGACGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCA

CGGACTCACCCCAGATCAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAAC

AGGCACTTGAGACGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGA

CTCACCCCAGATCAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGC

ACTTGAGACGGTTCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCA

CCCCAGATCAAGTTGTAGCGATTGCTAGTAACAATGGTGGCAAACAGGCTCTC

GAAACCGTACAACGACTCCTCCCAGTTCTCTGTCAAGCCCACGGACTAACTCC

TGATCAAGTTGTAGCGATTGCTAGTCATGACGGTGGCAAACAGGCTCTTGAGA

CCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCG

CAAGTTGTAGCGATTGCTAGTAATGGCggcggtcgaccggcgctggagagcat

tgttgcccagttatctcgccctgatccggcgttggccgcgttgaccaacgacc

acctcgtcgccttggcctgcctcggcggacgtcctgcgctggatgcagtgaaa

aagggattgccgcacgcgccggccttgatcaaaagaaccaatcgccgtattcc

cgaacgcacatcccatcgcgttgccggatcccaactagtcaaaagtgaactgg

aggagaagaaatctgaacttcgtcataaattgaaatatgtgcctcatgaatat

attgaattaattgaaattgccagaaatcccactcaggatagaattcttgaaat

gaaggtaatggaattttttatgaaagtttatggatatagaggtgagcatttgg

gtggatcaaggaaaccggacggagcaatttatactgtcggatctcctattgat

tacggtgtgatcgtggatactaaggcttatagcggaggttataatctgccaat

tggccaagcacgagaaatgcaacgatatgtcgaagaaaatcaaacacgaaaca

aacatatcaaccctaatgaatggtggaaagtctatccatcttctgtaacggaa

tttaagtttttatttgtgagtggtcactttaaaggaaactacaaagctcagct

tacacgattaaatcatatcactaattgtaatggagctgttcttagtgtagaag

agcttttaattggtggagaaatgattaaagccggcacattaaccttagaggaa

gtgagacggaaatttaataacggcgagataaacttt

R184P-
MAPKKKRKVYPYDVPDYAGYPYDVPDYAGSYPYDVPDYAAHGTVDLRTLGYSQ
SEQ ID

FokI
QQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIA
NO. 16

ALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGG

VTAVEAVHAWRNALTGAPLNLTPEQVVAIASHDGGKQALETVQRLLPVLCQAH

GLTPAQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQA

LETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQAHGLTP

AQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETV

QRLLPVLCQAHGLTPAQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPDQVV

AIASNIGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNNGGKQALETVQRLL

PVLCQAHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIAS

HDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGKQALETVQRLLPVLC

QAHGLTPAQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGG

KQALETVQRLLPVLCQAHGLTPAQVVAIASNIGGKQALETVQRLLPVLCQAHG

LTPDQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGRPAL

ESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLPHAPALIKRTNR

RIPERTSHRVAGSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNPTQDRI

LEMKVMEFFMKVYGYRGEHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYN

LPIGQADAMQSYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYK

AQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF*

R184P-
cgccattctgcctggggacgtcggagcaagcttgatttaggtgacactataga
SEQ ID

FokIN
atacaagctacttgttctttttgcaggatctgccaccatggctccaaagaaga
NO. 17

agcgtaaggtatacccatacgatgttcctgactatgcgggctatccctatgac

gtcccggactatgcaggatcgtatccatatgacgttccagattacgctgctca

tggtaccgtggatctacgcacgctcggctacagccagcagcaacaggagaaga

tcaaaccgaaggttcgttcgacagtggcgcagcaccacgaggcactggtcggc

cacgggtttacacacgcgcacatcgttgcgctcagccaacacccggcagcgtt

agggaccgtcgctgtcaagtatcaggacatgatcgcagcgttgccagaggcga

cacacgaagcgatcgttggcgtcggcaaacagtggtccggcgcacgcgctctg

gaggccttgctcacggtggcgggagagttgagaggtccaccgttacagttgga

cacaggccaacttctcaagattgcaaaacgtggcggcgtgaccgcagtggagg

cagtgcatgcatggcgcaatgcactgacgggtgcccccctgaacctgaccccg

gagcaggtggtggccatcgcTAGTCATGACGGTGGCAAACAGGCTCTTGAGAC

CGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCGC

AAGTTGTAGCGATTGCTAGTAATGGGGGTGGCAAACAGGCTCTTGAAACCGTG

CAACGACTGCTCCCAGTTCTCTGTCAAGCCCACGGCCTCACCCCGGCGCAAGT

TGTAGCGATTGCTAGTCATGACGGTGGCAAACAGGCTCTTGAGACCGTCCAAC

GCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCGCAAGTTGTA

GCGATTGCTAGTCATGACGGTGGCAAACAGGCTCTTGAGACCGTCCAACGCCT

TCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCGCAAGTTGTAGCGA

TTGCTAGTAATGGGGGTGGCAAACAGGCTCTTGAAACCGTGCAACGACTGCTC

CCAGTTCTCTGTCAAGCCCACGGCCTCACCCCGGCGCAAGTTGTAGCGATTGC

TAGTCATGACGGTGGCAAACAGGCTCTTGAGACCGTCCAACGCCTTCTACCAG

TTCTCTGTCAAGCCCACGGACTAACCCCAGCGCAAGTTGTAGCGATTGCTAGT

AATATTGGTGGCAAACAGGCACTTGAGACGGTTCAGCGCCTCCTTCCAGTTCT

TTGTCAAGCTCACGGACTCACCCCAGATCAAGTTGTAGCGATTGCTAGTAATA

TTGGTGGCAAACAGGCACTTGAGACGGTTCAGCGCCTCCTTCCAGTTCTTTGT

CAAGCTCACGGACTCACCCCAGATCAAGTTGTAGCGATTGCTAGTAACAATGG

TGGCAAACAGGCTCTCGAAACCGTACAACGACTCCTCCCAGTTCTCTGTCAAG

CCCACGGACTAACTCCTGATCAAGTTGTAGCGATTGCTAGTAATGGGGGTGGC

AAACAGGCTCTTGAAACCGTGCAACGACTGCTCCCAGTTCTCTGTCAAGCCCA

CGGCCTCACCCCGGCGCAAGTTGTAGCGATTGCTAGTCATGACGGTGGCAAAC

AGGCTCTTGAGACCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGA

CTAACCCCAGCGCAAGTTGTAGCGATTGCTAGTAATGGGGGTGGCAAACAGGC

TCTTGAAACCGTGCAACGACTGCTCCCAGTTCTCTGTCAAGCCCACGGCCTCA

CCCCGGCGCAAGTTGTAGCGATTGCTAGTAATGGGGGTGGCAAACAGGCTCTT

GAAACCGTGCAACGACTGCTCCCAGTTCTCTGTCAAGCCCACGGCCTCACCCC

GGCGCAAGTTGTAGCGATTGCTAGTCATGACGGTGGCAAACAGGCTCTTGAGA

CCGTCCAACGCCTTCTACCAGTTCTCTGTCAAGCCCACGGACTAACCCCAGCG

CAAGTTGTAGCGATTGCTAGTAATATTGGTGGCAAACAGGCACTTGAGACGGT

TCAGCGCCTCCTTCCAGTTCTTTGTCAAGCTCACGGACTCACCCCAGATCAAG

TTGTAGCGATTGCTAGTAATGGGGGTGGCAAACAGGCTCTTGAAACCGTGCAA

CGACTGCTCCCAGTTCTCTGTCAAGCCCACGGCCTCACCCCGGCGCAAGTTGT

AGCGATTGCTAGTAATGGCggcggtcgaccggcgctggagagcattgttgccc

agttatctcgccctgatccggcgttggccgcgttgaccaacgaccacctcgtc

gccttggcctgcctcggcggacgtcctgcgctggatgcagtgaaaaagggatt

gccgcacgcgccggccttgatcaaaagaaccaatcgccgtattcccgaacgca

catcccatcgcgttgccggatcccaactagtcaaaagtgaactggaggagaag

aaatctgaacttcgtcataaattgaaatatgtgcctcatgaatatattgaatt

aattgaaattgccagaaatcccactcaggatagaattcttgaaatgaaggtaa

tggaattttttatgaaagtttatggatatagaggtgagcatttgggtggatca

aggaaaccggacggagcaatttatactgtcggatctcctattgattacggtgt

gatcgtggatactaaagcttatagcggaggttataatctgccaattggccaag

cagatgccatgcaaagctatgtcgaagaaaatcaaacacgaaacaaacatatc

aaccctaatgaatggtggaaagtctatccatcttctgtaacggaatttaagtt

tttatttgtgagtggtcactttaaaggaaactacaaagctcagcttacacgat

taaatcatatcactaattgtaatggagctgttcttagtgtagaagagctttta

attggtggagaaatgattaaagccggcacattaaccttagaggaagtgagacg

gaaatttaataacggcgagataaacttttaatctagaactatagtgagtcgta

ttacgtagatccagacatgataagatacattgatgagtttggacaaaccacaa

ctagaatgcagtgaaaaaaatgctttatttgtgaaatttgtgatgctattgct

ttatttgtaaccattataagctgcaataaacaagttaacaacaacaattgcat

tcattttatgtttcaggttcagggggaggtgtgggaggttttttaattcgcgg

ccgcggcgccaatgcattgggcccggtacgtacccagcttttgttccctttag

tgagggttaattgcgcgcttggcgtaatcatggtcatagctgtttcctgtgtg

aaattgttatccgctcacaattccacacaacatacgagccggaagcataaagt

gtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgc

tcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaat

cggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcct

cgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagct

cactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaa

gaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgt

tgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcga

cgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtt

tccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccg

gatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagetea

cgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgt

gcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtc

ttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggt

aacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtg

gtggcctaactacggctacactagaaggacagtatttggtatctgcgctctgc

tgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaa

accaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcag

aaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctc

agtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaagg

atcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaag

tatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcac

ctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtc

gtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaat

gataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagc

cagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatc

cagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatag

tttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgt

ttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatga

tcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgt

cagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcata

attctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtac

tcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgccc

ggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctca

tcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttg

agatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttt

tactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaa

aaaagggaataagggcgacacggaaatgttgaatactcatactcttccttttt

caatattattgaagcatttatcagggttattgtctcatgagcggatacatatt

tgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaa

aagtgccacctaaattgtaagcgttaatattttgttaaaattcgcgttaaatt

tttgttaaatcagctcattttttaaccaataggccgaaatcggcaaaatccct

tataaatcaaaagaatagaccgagatagggttgagtgttgttccagtttggaa

caagagtccactattaaagaacgtggactccaacgtcaaagggcgaaaaaccg

tctatcagggcgatggcccactacgtgaaccatcaccctaatcaagttttttg

gggtcgaggtgccgtaaagcactaaatcggaaccctaaagggagcccccgatt

tagagcttgacggggaaagccggcgaacgtggcgagaaaggaagggaagaaag

cgaaaggagcgggcgctagggcgctggcaagtgtagcggtcacgctgcgcgta

accaccacacccgccgcgcttaatgcgccgctacagggcgcgtcccattcgcc

attcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttcgctat

tacgccagtcgattatatactcgagatatatttcgaccatagccaattcaata

tggcgtatatggactcatgccaattcaatatggtggatctggacctgtgccaa

ttcaatatggcgtatatggactcgtgccaattcaatatggtggatctggaccc

cagccaattcaatatggcggacttggcaccatgccaattcaatatggcggact

tggcactgtgccaactggggaggggtctacttggcacggtgccaagtttgagg

aggggtcttggccctgtgccaagtccgccatattgaattggcatggtgccaat

aatggcggccatattggctatatgccaggatcaatatataggcaatatccaat

atggccctatgccaatatggctattggccaggttcaatactatgtattggccc

tatgccatatagtattccatatatgggttttcctattgacgtagatagcccct

cccaatgggcggtcccatataccatatatggggcttcctaataccgcccatag

ccactcccccattgacgtcaatggtctctatatatggtctttcctattgacgt

catatgggcggtcctattgacgtatatggcgcctcccccattgacgtcaatta

cggtaaatggcccgcctggctcaatgcccattgacgtcaataggaccacccac

cattgacgtcaatgggatggctcattgcccattcatatccgttctcacgcccc

ctattgacgtcaatgacggtaaatggcccacttggcagtacatcaatatctat

taatagtaacttggcaagtacattactattggaaggacgccagggtacattgg

cagtactcccattgacgtcaatggcggtaaatggcccgcgatggctgccaagt

acatccccattgacgtcaatggggaggggcaatgacgcaaatgggcgttccat

tgacgtaaatgggcggtaggcgtgcctaatgggaggtctatataagcaatgct

cgtttagggaac

BAT1206F
QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNL
SEQ ID

light
ASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK
NO. 18

chain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ

ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE

C

BAT1206F
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYP
SEQ ID

heavy
GNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDW
NO. 19

chain
YFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT

VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN

TKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC

LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG

NVFSCSVMHEALHNHYTQKSLSLSPGK

BAT4306F
DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLI
SEQ ID

light
YQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGG
NO. 20

chain
TKVEIKR

BAT4306F
QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFP
SEQ ID

heavy
GDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWL
NO. 21

chain
VYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK

VDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV

KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV

FSCSVMHEALHNHYTQKSLSLSPGK

BAT4406F
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASN
SEQ ID

light
RATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEI
NO. 22

chain
KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS

QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS

FNRGEC

BAT4406F
EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISW
SEQ ID

heavy
NSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYY
NO. 23

chain
YGMDVWGQGTTVTVSSASTKGPSVFPLAPGSSKSTSGTAALGCLVKDYFPEPV

TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS

NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT

CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW

LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT

CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQKSLSLSPGK

BAT0206F
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASN
SEQ ID

light
LETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEI
NO. 24

chain
KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS

QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG

EC

BAT0206F
QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHI
SEQ ID

heavy
YYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAF
NO. 25

chain
DIWGQGTTVTVSSACTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK

VDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV

KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV

FSCSVMHEALHNHYTQKSLSLSPGK

BAT0808
DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASY
SEQ ID

light
RYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEI
NO. 26

chain
KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS

QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG

EC

BAT0808
QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINT
SEQ ID

Heavy
YTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYW
NO. 27

chain
YFDVWGQGTLVTVSSCSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT

VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN

TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC

LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG

NVFSCSVMHEALHNHYTQKSLSLSPGK

CHO-BAT-
ATGCGGGCATGGACTGGTTCCTGGCGTTGGATTATGCTCATTCTTTTTGCCTG
SEQ ID

KF Exon1
GGGGACCTTATTGTTTTATATAGGTGGTCATTTGGTTCGAGATAATGACCACC
NO. 28

CTGACCATTCTAGCAGAGAACTCTCCAAGATTCTTGCAAAGCTGGAGCGCTTA

AACAACAAAATGAAGACTTGAGGAGAATGGCTGAGTCTCTCCGG

Example 3. Functional Effectiveness Analysis of FUT8 TALEN Protein

CEL-I enzyme is a nuclease that can recognize the mismatched bases in double-stranded DNA and cut the double-stranded DNA from the mismatches. If the target sequence is edited by FUT8TALEN, the fragment containing the target sequence amplified from the maternal genome and the fragment containing the target sequence amplified from the transformed cell genome are mixed together for denaturation and annealing, the annealed double-stranded DNA will appear base mismatch. In this case, CEL-I enzyme can cut off the annealed double-stranded DNA, and two bands appear as a result of agarose electrophoresis. 5×10⁵CHO-BAT cells were seeded into a 6-well plate on the day before transfection, and the medium was DMEM/F12 containing 10% fetal calf serum. Plasmids L130N and R184N were transiently transfected into cells according to the methods provided in the reagent instructions. 3 days after transfection, the cells were harvested by centrifugation and the genome was extracted with the genome extraction kit. Using this as a template, PCR reaction was carried out with the primers L130 for (SEQ ID NO. 1) and primer L130rev (SEQ ID NO. 2). The PCR amplification of the fragment of the parent cell containing the target sequence was the same as above. 20 μL of two PCR products were mixed together, heated to 94° C. and then naturally cooled to room temperature. Added 0.5 μl of CEL-I enzyme to 200 ng annealed DNA, and incubated at 42° C. for 30 min, and ran the PCR reaction product on agarose gel electrophoresis. The reaction product was analyzed by agarose electrophoresis, and the results are as shown in FIG. 3.

The results show that, compared with the wild type, the gene-edited PCR products displayed two bands of 500 bp and 750 bp, while the wild type only had a single band of 750 bp, which is consistent with the expected results. This proves that TALEN protein pairs are functional.

Example 4. Effect of FUT8 TALEN Protein on Antibody Fucose Content

To determine whether the host genome adjusted by the designed FUT8 TALEN protein affects the carbohydrate chain of the produced antibody (whether the fucose content changes or not), L130N and R184N plasmids are transiently transformed into previously established cell lines stably expressing anti-CD20 antibodies. The methods provided in lipofectamine 2000 (Invitrogen) reagent description was taken and briefly described as follows. In a 10 cm cell culture dish, 24 μL of liposomes packed with 4 μg of plasmid DNA of L130N and R184N were added to 1×10⁶cells. After transfection for two days, the medium was replaced into DMEM/F12 medium containing 10% (V/V) FBS (GBICO) and 400 μg/mL LCA (Vector). After one week, most of the cells became round and suspended in the medium, while others grew normally on the wall. The supernatant was discarded, and LCA-resistant cells were digested with trypsin 0.25% (v/v), and resuspended in DMEM/F12 medium containing 10% (v/v) FBS after centrifugation. The cells were seeded in the 96-well plate at a density of 0.5 per well. After two weeks, monoclonal cells were selected and transferred to a 24-well plate. FACS was adopted to analyze the cells grown on a 24-well plate, and FITC labeled LCA bound to negative cells (FIG. 4) were propagated to produce antibodies. The oligosaccharide content of antibodies produced by the two cells was determined by Biodonor, and the results are shown in FIG. 5.

The results show that the fucose content of antibody was reduced when plasmids L130 and R184 were transiently transformed into antibody-producing cells.

Example 5. Establishment of Genome-Modified Host Cells

In order to establish a genome-modified CHO-K1 cell so that it can be the host cells used as proteins and fucose-free antibodies, the plasmids L130 and R184 were transiently transformed into CHO-K1 cell lines. The screening of monoclonal cells against LCA was described in example 3. The genome of candidate cell clones was extracted respectively, PCR reaction was carried out with the primer L130 for (see Table 1, SEQ ID NO. 1) and the primer L130rev (see Table 1, SEQ ID NO. 2), and CEL-1 base mismatch analysis was carried out on PCR amplification products of fragments containing target sequences of candidate cell clones. If the candidate clone was heterozygous, then the agarose electrophoresis after CEL-1 enzyme digestion showed two bands; instead, if the candidate clone was homozygous, then the annealed fragment could not be cleaved through CEL-1 enzyme digestion, and the agarose electrophoresis showed one band. The PCR fragment was cloned directly into a T vector (pGEM-T Easy Vector) and then sequenced. The sequencing result was compared with the sequence of the parent cell in this fragment as shown in FIG. 6. Then, according to the comparison result, two genome-edited homozygotes were selected and designated as CHO-2G8, CHO-1D6.

Example 6: Evaluation of Growth Characteristics of Host Cells

The FUT8 gene knockout cloned CHO-2G8 was selected as the host cell and renamed as CHO-BAT-KF. Three CHO-BAT-KFs and one CHO-BAT were respectively seeded in 30 mL CD CHO AGT™ with a final concentration of 6 mM Gln in a 125 mL shake flask at the cell density of 300000/ml, and 0.5 mL of cells were taken at d0, d3, d6 and d7, respectively, to measure the cell density and cell viability and evaluate the change of cell growth characteristics after the FUT8 gene was knocked out. The cell growth density is shown in FIG. 7 and the cell growth viability is shown in FIG. 8. As can be seen from FIG. 7 and FIG. 8, no significant difference was observed in growth density and viability between FUT8 gene knock-out CHO-BAT-KF and CHO-BAT cells with FUT8 gene not knocked out.

Example 7. Analysis of Glycosylation Profile of Antibodies Produced by Host Cells

In order to determine that the carbohydrate chain of the antibody produced by the genome-modified CHO-2G8 cell line according to the present invention has aberrant N-polysaccharide modification, BAT4306F produced by CHO-2G8 cells and 4306 produced by CHO-K1 cells were purified from the medium through a protein A affinity column and quantified by UV280. Desalinated monoclonal antibody (1 mg) was incubated with PNGaseF overnight at 37° C. to release N-glycan from the antibody. The released N-glycan was separated from the antibody by 30K Amicon ultrafiltration, lyophilized and resuspended in 200 μL deionized water. MALDI-TOF MS was used to analyze N-polysaccharides from two antibody molecules as described above. Oligosaccharides from the antibody BAT4306F produced by CHO-2G8 existed in a single peak and were basically the same population, which was different from the profile of the antibody 4306 oligosaccharides produced by parent host cells (FIG. 9).

The results show that the three peaks of N-polysaccharide of 4306 were G0F, G1F and G2F, respectively. Based on the peak time and molecular weight of N-polysaccharide from BAT4306F, it was inferred that the three peaks of N-polysaccharide are G0, G1 and G2; that was, each N-polysaccharide from BAT4306F was one fucose less than the N-polysaccharide from 4306.

At the same time, commercially available Gazyva was compared with the carbohydrate chains of BAT4306F to analyze the heterogeneity of their carbohydrate chains, as shown in FIG. 10. The results show that BAT4306F had lower N-polysaccharide heterogeneity and a more uniform carbohydrate chain. The glycotypes of different antibodies expressed in CHO-BAT-KF cells were analyzed as shown in Table 4.

Example 8. Analysis of ADCC Activity of Antibodies Produced by Host Cells

In order to determine whether the modification of the antibody having the N-polysaccharide of the present invention can improve its biological function (e.g., ADCC activity), the purified antibodies targeting CD20 are used to determine their ADCC activity in vitro (LDH method promega). The BAT4306F antibody produced by CHO-2G8 was purified through protein A affinity column and was quantified by UV280. The parent unmodified 4306 was expressed in wild-type CHO cells and purified in the same way. To carry out ADCC detection, the wil2-S cells were cultured in RPMI-1640 medium containing 10% FBS in good condition (4-7 days). Centrifuged cells in logarithmic growth phase at 1000 rpm for 10 min to remove supernatant. Added solution A (RPMI-1640 culture medium without phenol red and containing 10% FBS) and mixed well, centrifuged twice as above, counted, adjusted the number of cells to 3×10⁵cells/ml with solution A, and added it to U-96 cell culture plate at 100 μl per well. Adjusted the final concentration of antibody to 1.2, 0.24, 0.048, 0.0096, 0.00192, 0.000384, 0.0000768 and 0.00001536 (μg/mL) sequentially. Incubated at 37° C. for 30 min in a 5% CO₂incubator. Collected the effector cells PBMC, added solution B (RPMI-1640 culture medium without serum and phenol red) and centrifuged twice as above, counted, adjusted the number of cells to 3×10⁵cells/ml with solution B, and added it to the U-96 cell culture plate at 50 μl per well. Incubated at 37° C. for 3 h in a 5% CO₂incubator. When there was still 45 min from the incubation time of 3 h, added 20 μl of lysate to the well of maximum release target cell, and then incubated in a 5% CO₂incubator at 37° C. for 45 min. Placed the U-96 well cell culture plate in a centrifuge and centrifuged at 250 g for 4 min. Taken 50 μl/well supernatant to another 96-well plate with flat bottom, added 50 μl/well of prepared chromogenic fluid, gently shaken and mixed, and reacted for 30 min at room temperature without light. Added 50 μl/well of the stop solution and gently shaken and mixed. Read the results at the microplate reader OD490.

The results show that, compared with non-modified 4306 produced by the parent CHO cells, BAT4306F of N-polysaccharide produced by CHO-2G8 cell cloning in serum-free medium significantly increased ADCC activity on Raji cells and wil2-S cells (FIG. 11).

Example 9. Analysis of Affinity of Antibodies Produced by Host Cells to CD20

In order to determine whether the antibody with modified N-polysaccharide produced by the cell according to the present invention has an effect on the ability to bind CD20-positive cells, BAT4306F and 4306 were verified by the FASC method by reference to Klervi Even-Desrumeaux et al. (2012), and the affinity of Rituximab to CD20 on different cell surfaces was compared, as described briefly below; collected Wil2-s cells in the logarithmic growth phase, centrifuged at 800 rpm for 5 min, and discarded supernatant. Washed once with PBS, calculated density, resuspended in PBS, and packed into 1.5 mL centrifuged tubes to make 500,000 cells per tube. Centrifuged at 1200 rpm for 5 min and discard supernatant. Prepared the antibody at concentrations of 30, 3.33, 1.11, 0.37, 0.1, 0.04, 0.014 and 0.0046 μg/mL, respectively, added 200 μl of antibody to the cells sequentially, resuspended the cells and mixed evenly. At the same time, added PBS of the same volume as the negative control. Kept away from light at 4° C. for 2 h. Centrifuged at 1200 rpm for 5 min, discarded supernatant and washed once with PBS. Added 100 μl of PBS to resuspend cells, added 2 μl of secondary antibody of FITC-sheep anti-human IgG1 Fab, and kept in dark place at 4° C. for 30 min. Centrifuged at 1200 rpm for 5 min, discarded supernatant and washed once with PBS. Detected with the C6 flow cytometer. Based on the formula Kd=[Ab]*{Fmax/(F−Fback)−1}, the results are shown in the following table.

TABLE 2

Statistical results of IC₅₀and Kd values of antibody-to-cell binding experiments